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Abstract 
Objective: To evaluate the medication adherence of individuals participating in a pharmacist-run employee health Cardiovascular 
and Diabetes Risk Reduction Program. Design: Retrospective analysis of medication adherence using pharmacy refill data. Setting: A 
medium sized university located in the Midwest United States and the organization’s outpatient pharmacy. Participants: 38 
participants ≥ 18 years of age, employed and  receiving their health insurance through the organization, and have a diagnosis  of 
hypertension, hyperlipidemia, diabetes mellitus, or a combination thereof. Intervention: Participation in the risk reduction program 
that emphasizes medication therapy management (MTM), lifestyle medicine and care coordination. Main Outcome Measures: The 
Proportion of Days Covered (PDC) and the Medication Possession Ratio (MPR). Results: PDC and MPR analysis showed a statistically 
significant improvement in medication adherence for 180 days and 360 days post enrollment versus the 180 days prior to enrollment 
(P<0.01). The PDC analysis demonstrated a statistically significant improvement in the number of medications that achieved a PDC ≥ 
80% (high adherence) for the 180 days post enrollment versus the 180 days prior to enrollment (+30%, P<0.01). The MPR analysis 
showed a non-statistically significant improvement in the number of medications that achieved an MPR ≥ 80% (high adherence) pre 
enrollment versus post enrollment (+10%, P=0.086). The percentage of participants in the program that reached a PDC and MPR 
adherence rate ≥ 80% at 180 days post enrollment was 78.9% and 94.4%, respectively which exceeds that of a matched cohort that 
reached a PDC and MPR adherence rate ≥ 80% of 66.4% and 82.8%, respectively. Conclusion: Pharmacists can improve medication 
adherence as measured by PDC and MPR when working with employees enrolled in a novel pharmacist-run employee health risk 
reduction program. Medication adherence was shown to be sustainable for at least one year and was shown to be better when 
compared to a matched cohort of similar age, condition and region.   
 
 
Introduction 
The World Health Organization defines adherence as “the 
extent to which a person’s behavior – taking medication, 
following a diet, and/or executing lifestyle changes – 
corresponds with agreed recommendations from a 
healthcare provider.”
1
 The term adherence implies active 
participation by the patient whereas compliance refers to a 
passive role. With adherence, the patient is collaborating 
with their healthcare provider and not simply following 
“doctor’s orders.” 
 
 
Medication non-adherence is considered to be our nation’s 
“other drug problem.”
2
 It is estimated that 50% percent of 
patients with chronic conditions are non-adherent to their 
medication therapy.
3
 Adherence to chronic medications is 
often lower than adherence to acute medications.
4
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Medication non-adherence can lead to substantial health and 
economic consequences. According to an estimate from the 
Office of the Inspector General, 10% of hospital admissions 
are due to medication non-adherence, and approximately 
125,000 deaths from cardiovascular disease per year in the 
United States are due to medication non-adherence.
1
 
Medication non-adherence leads to an estimated $100 billion 
dollars per year in medication related hospital admissions in 
the U.S.
4
      
 
The proportion of days covered (PDC) and the medication 
possession ratio (MPR) are two methods of measuring 
medication adherence using pharmacy refill or claims data.
5
 A 
PDC and MPR ≥ 80% is considered high adherence and is the 
benchmark most commonly reported in the literature.
5
  
 
The primary objective of this analysis was to evaluate the 
change in medication adherence of individuals participating 
in a pharmacist-run risk reduction program using both the 
proportion of days covered (PDC) and the medication 
possession ratio (MPR). The project was submitted to the 
local Institutional Review Board for approval and oversight. 
The project was considered to be a continuous quality 
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improvement measure of the risk reduction program and 
therefore, oversight was deemed unnecessary.  
 
Methods 
Risk Reduction Program 
In 2008, a medium sized university in the Midwestern section 
of the United States initiated a pharmacist-run employee 
health Cardiovascular and Diabetes Risk Reduction Program.  
Employees were eligible to volunteer for the program if they 
had an existing diagnosis of hypertension, 
hypercholesterolemia, diabetes mellitus, or a combination 
thereof.  Employees could participate in the program for as 
long as they remained employed with the university and 
obtained their health care benefits from the employer.  The 
primary outcomes of the program were to (1) reduce the risk 
of experiencing a cardiovascular event within the next 10 
years; (2) improve the lifestyle habits of physical activity, 
healthy eating, stress management, sleeping, alcohol 
consumption, and tobacco use; (3) improve medication 
adherence; (4) improve quality of life; and (5) improve 
presenteeism rates.  
 
Participants in the risk reduction program attended one-on-
one appointments with the pharmacist at least one time per 
month.  Monthly visits consisted of medication therapy 
management activities, implementation and adherence to 
seven personalized lifestyle medicine programs (physical 
activity, healthy eating, stress management, restorative 
sleep, moderate alcohol consumption, tobacco 
abstinence/cessation, and weight control), and chronic 
disease education and care coordination practices.
6
  
Information regarding the care coordination practices within 
the program has been previously published.
7
 
 
In order to achieve the highest level of program adherence 
and success, each participant was provided with educational 
materials, a home blood pressure monitor, a pedometer, 
lifestyle behavior tracking tools, free access to the employer’s 
exercise facilities, monthly support group meetings, and 
access to a licensed mental health care provider.   
 
Individual participant data was collected at baseline and 
annually thereafter.  Collected data consisted of medication 
refill records, cholesterol, blood pressure, and blood glucose 
lab values, body weight, lifestyle behavior activities, health 
related quality of life questionnaires, and work productivity 
questionnaires.  With the permission of the participant, 
additional health information was also obtained from the 
annual health risk appraisal data collected by the employer 
and/or from the participants other health care professionals 
(i.e. physician). 
 
Medication Adherence Analysis 
Medication-related data were collected for each participant 
for six months prior to enrollment in the program and for one 
year after enrollment in the program.  The medication related 
data for each oral medication used to treat hypertension, 
hyperlipidemia and diabetes included: name, strength, 
quantity, dosage unit per day, national drug code (NDC), date 
of first fill and date of subsequent refills. Days’ supply was 
calculated based on quantity dispensed and dosage unit per 
day. Medications were excluded if they were non-oral or if 
they did not have a quantifiable days supply. The proportion 
of days covered (PDC) and the medication possession ratio 
(MPR) were used to measure adherence for each participant.  
 
The PDC was calculated as the number of days during the 
analysis period on which medication was available to the 
participant (total days supplied) divided by the total number 
of days in the analysis period. The PDC was truncated at 1.00 
by removing any days of therapy extending beyond the 
analysis period, resulting in a ratio ranging between 0 and 1.  
 
MPR was calculated as the total days supplied of medication 
between the first prescription and the end of days supplied 
associated with the participant’s final prescription in the 
follow-up period (regardless of gaps in therapy), divided by 
the total number of days between the participant’s first fill 
date and the end of days supplied for the participant’s final 
prescription in the analysis period. The MPR was truncated at 
1.00 by removing any days of therapy extending beyond the 
analysis period. Participants with only one medication in the 
analysis period were not analyzed for MPR.  
 
Participant medication adherence for 360 days after 
enrollment in the program was compared with their 
adherence for 180 days leading up to enrollment in the 
program. Also, adherence results were compared to 
benchmark data obtained from the IMS Lifelink Integrated 
Health Plan Claims Database within the Disease Cohort 
Analytic module of the Insight Data & Analytics (iDNA) tool.
 8
 
The matched cohort benchmark data is comprised of 
commercial, self-insured and Medicare Advantage data. 
Individuals included in the current analysis were matched to 
individuals in the database using age, diagnosis, treatment 
time period, and region of the country.  The time period 
chosen for the matched cohort was similar to that of the 
participants for year (2009) and follow-up (180 days). 
 
Participants  
The individuals included in this analysis were participants in 
the risk reduction program enrolled between August 2008 
and December 2009.  
 
Original Research PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                        2012, Vol. 3, No. 4, Article 92                          INNOVATIONS in pharmacy   3 
 
Statistical Analysis 
For each participant included in the analysis, PDC and MPR 
were summarized by mean, standard deviation, median, and 
the number (%) attaining a threshold of ≥ 80% (high 
adherence). The PDC was calculated at a medication class 
level and MPR was calculated at both the medication class 
and product levels, both using an intent-to-treat analysis. 
 
A paired t-test was used to compare the PDC and MPR on a 
medication class level before and after enrollment in the 
program. A two sample t-test was used to compare the PDC 
and MPR for participants before and after enrollment in the 
program. 
 
Results 
Participant population characteristics 
There were 48 participants enrolled in the risk reduction 
program between August 2008 and December 2009. A total 
of 38 participants had pharmacy refill data available and were 
included in the PDC analysis. A total of 36 participants had 
pharmacy refill data available and were included in the MPR 
analysis. The differing methods of calculating the PDC and 
MPR account differing number of participants included in 
each analysis.  The average age of the 38 study participants 
for the PDC analysis was 52 years, with 27 females and 11 
males. The number of participants for the PDC analysis with a 
diagnosis of hypertension, hyperlipidemia and diabetes 
mellitus were 27, 24, and 10, respectively. The average age of 
the 36 study participants for the MPR analysis was 52 years, 
with 26 females and 10 males. The number of participants for 
the MPR analysis with a diagnosis of hypertension, 
hyperlipidemia, and diabetes mellitus was 25, 22, and 10, 
respectively. For the PDC analysis, there were 53 medication 
refill occurrences that matched for participant identification 
and medication class and 44 matching medication refill 
occurrences for the MPR analysis. Again, differing methods of 
calculating the PDC and MPR account for the differing 
number of medication refill occurrences that can be counted 
in each analysis.   
Adherence Analysis 
Table 1 compares PDC and MPR prior to enrollment versus 
post enrollment. Both PDC and MPR analysis showed a 
statistically significant improvement in medication adherence 
for 180 days and 360 days post enrollment versus the 180 
days prior to enrollment (P<0.01). 
Table 2 compares the percentage of medications matched for 
participant identification and medication class that achieved 
a PDC and MPR ≥ 80% (high adherence) for 180 days prior to 
enrollment versus 180 days post enrollment. The PDC analysis 
showed a statistically significant improvement in the number 
of medications that achieved high adherence for the 180 days 
post enrollment versus the 180 days prior to enrollment 
(+30%, P<0.01). The MPR analysis demonstrated a non-
statistically significant improvement in medication adherence 
of 10% (P=0.086).  
The matched cohort data consisted of 203,580 individuals 
between the ages of 30 to 64 years with the diagnosis of 
dyslipidemia in the Midwest region of the United States for a 
180 day time period in the year 2009.
8
  
  
The comparison 
showed that more participants in the risk reduction program 
achieved a PDC and an MPR ≥ 80% when compared to the 
matched cohort. The percentage of participants in the 
program that reached a PDC and MPR adherence rate ≥ 80% 
for 180 days post enrollment was 78.9% and 94.4%, 
respectively. The percentage of participants in the matched 
cohort that attain a PDC and MPR adherence rate ≥ 80% 
during a 180 follow-up period was 66.4% and 82.8%, 
respectively. 
A follow up analysis compared PDC and MPR for their ability 
to estimate medication adherence. The results showed that 
MPR overestimated adherence by 6.4% compared to PDC. 
The overestimation of adherence by MPR, however, was not 
statistically significant (P=0.082).  
Discussion 
The results of this analysis suggest that medication adherence 
can be improved in individuals who participate in the 
pharmacist-led Cardiovascular and Diabetes Risk Reduction 
Program in an employee health setting. The results also 
suggest that participants in the program have higher 
adherence rates when compared to a matched cohort, and 
that the improved medication adherence can be sustained for 
at least 360 days post enrollment in the program. 
Pharmacists play an important role in improving medication 
adherence and health outcomes. Previously published 
studies, such as the Asheville Project and Project IMPACT, 
have also demonstrated that pharmacist-led patient care 
services can improve medication adherence,  health 
outcomes and decrease overall healthcare costs in patients 
with chronic conditions.
9-12
   
Barriers to medication adherence can include cost, lack of 
perceived importance, complexity of medication regimens, 
undesirable side effects, forgetfulness and difficulty of 
administration.
12
 The risk reduction program addresses a 
number of these barriers in an effort to improve medication 
adherence. [TABLE 3] The program has found that working 
individually with the participants has a significant impact on 
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success with implementing positive health behaviors, 
including taking medications.  Participants in the program 
meet one-on-one with a pharmacist at least one time each 
month.  The pharmacist and participant discuss the 
importance of taking medications as directed, work on 
individualized strategies to improve adherence, and conduct 
comprehensive medication therapy management (MTM). 
MTM for the program participants includes reviewing the 
most up-to-date medication and natural products lists for 
potential interactions, adverse effects, efficacy, and simplicity 
of the medication regimen. When possible, medication 
regimens are simplified to allow for once a day scheduling 
rather than multiple times per day scheduling. Also, 
unnecessary medications are discontinued whenever 
possible.  
 
An effective method of modifying health behaviors can occur 
through the use of tracking tools, diaries and/or journaling.  
The program developed a comprehensive lifestyle journal 
that allows participants to record lifestyle behaviors on a 
daily basis, including medication adherence. The lifestyle 
journal helps remind the participants to take their 
medications as well as be accountable for their lifestyle 
behaviors as they are required to bring their lifestyle journal 
to each visit with the pharmacist.  Additionally, the program 
supplies a pill box free of charge to any participant wishing to 
use one to help improve medication adherence.  
 
A significant barrier to medication adherence can also be 
related to the cost of medication(s). An incentive program 
was implemented with the participants included in this 
analysis to receive their medications for hypertension, 
hyperlipidemia and diabetes at no cost for their first 18 
months of participation if they met certain program 
adherence criteria.  It should be noted that the free 
medication benefit may have removed the cost barrier and 
improved medication adherence.  
 
Medication non-adherence has been shown to be associated 
with greater healthcare costs. It is estimated that a midsize 
employer in the U.S. with $10 million in annual healthcare 
claims may be wasting approximately $1 million per year in 
avoidable healthcare costs due to drug related morbidity, 
including non-adherence.
13
 In 2010 the total direct national 
cost of non-adherence, defined as an MPR < 80%, for adults 
with diabetes, hypertension and dyslipidemia was estimated 
to be $105.8 billion.
14
 Additionally, this analysis showed that 
for every person in Nebraska (state which this current 
analysis took place) with hypertension, hyperlipidemia and 
diabetes who does not achieve an MPR ≥ 80%, it costs 
$356.09 per year in direct medical costs.
14
 In our analysis, a 
net of three CVRRP participants with an MPR below 80% prior 
to enrolling in the program, reached an MPR ≥ 80% by 180 
days post enrollment. This suggests that the program may 
have saved $1068.27 in direct medical costs in the first year 
by improving medication adherence. It should be noted that 4 
of the 36 individuals included in the MPR analysis improved 
their medication adherence from a level less than 80% to a 
level greater than 80% after beginning the program.  
Additionally, one individual decreased adherence from 
greater than 80% to less than 80% after starting the program.  
It should further be noted that the cost avoidance 
estimations stated above does not take into account indirect 
costs associated with medication non-adherence.    
There is no consensus on an optimal method of measuring 
medication adherence.
15 
The majority of studies use some 
form of the MPR calculation.
5
 However, MPR does not 
account for gaps in therapy and is reported to often 
overestimate adherence.
16
 An increasing number of studies 
and organizations including Center for Medicare and 
Medicaid Services (CMS) are currently using PDC to measure 
adherence with refill and claims data. The PDC method 
accounts for gaps in therapy and does not overestimate 
adherence. We used both the PDC and MPR methods to be 
consistent with the majority of the published literature and to 
account for the method used by CMS.  Due to the reports 
that MPR has the potential to overestimate medication 
adherence, we did a follow up analysis of our data comparing 
PDC to MPR.  The results showed that MPR overestimated 
adherence by 6.4% (P=0.082). This non-statistically significant 
finding may have been due to the small sample size and we 
plan to continue to monitor both MPR and PDC in our 
program participants. 
Although our medication adherence analysis was positive, it 
was not without a number of limitations. The sample size for 
this analysis was small and the analysis period ended at one 
year.  One of the goals of the program is to achieve long-term 
medication adherence of > 80% and therefore, further 
analyses of a larger cohort for a longer period of time is 
needed to show long-term achievement. Also, medication 
adherence was only calculated for oral hypertension, 
hyperlipidemia and diabetes mellitus medications.  
Medications used for other indications and non-oral 
medications (e.g. insulin) were not included. Medications 
were only included if they had a quantifiable days supply. It 
was not possible to calculate a PDC or MPR for any 
medication taken on an “as needed” basis or with a variable 
dosage unit per day. Also, adherence analysis based on refill 
data describes how much medication the participant had the 
opportunity to take, not what the participant actually 
ingested. This analysis only included medications filled at the 
organization’s pharmacy which is where the participants filled 
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their prescriptions. It doesn't account for medication received 
at other pharmacies or by other means (e.g. samples). Lastly, 
the matched cohort for this analysis was not controlled, and 
the matched cohort only included individuals with the 
diagnosis of dyslipidemia.  It is unknown if the matched 
cohort had a diagnosis of hypertension and/or diabetes. 
Future analyses of medication usage in risk reduction 
participants will include the cost effectiveness of the 
intervention so that a return on investment may be 
calculated. 
 
Conclusion 
Medication non-adherence has shown to be a significant 
problem in healthcare, both in prevalence and in economic 
burden.  This analysis showed that pharmacists can improve 
medication adherence as measured by PDC and MPR when 
working with employees enrolled in a novel pharmacist-run 
employee health risk reduction program.  The medication 
adherence was shown to be sustainable for at least one year 
and was shown to be better when compared to a matched 
cohort.  Strategies such as frequent one-on-one 
appointments with the pharmacists may be an effective way 
to improve medication adherence, but the cost effectiveness 
of this intervention needs to be analyzed. 
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Table 1. Comparison of PDC and MPR for 180 days prior to enrollment versus a 360 day time period  
post enrollment in a pharmacist-run risk reduction program. 
 180 days prior 
to enrollment 
(Baseline) 
180 days post 
enrollment 
Adherence 
Change vs. 
Baseline (P 
value) 
360 days post 
enrollment 
Adherence 
Change vs. 
Baseline 
(P value) 
PDC 
(n=53*) 
0.79 ±0.25 0.96 ±0.11 
 
+17% 
P<0.001 
0.94±0.13 +15%  
P<0.001 
MPR  
(n=44*) 
0.92 ±0.11 0.96 ±0.06 
 
+4% 
P=0.001 
No data No data 
PDC: Proportion of Days Covered 
MPR:  Medication Possession Ratio 
SD:  Standard Deviation 
*Number of occurrences matched for participant identification and medication class 
 
 
Table 2. Percentage of medications achieving a PDC and MPR ≥ 80% (high adherence) for 180 days prior  
to enrollment versus the 180 days post enrollment. 
 180 days prior to 
enrollment 
180 days post 
enrollment 
Difference 
(P value) 
PDC*  56% (n=62) 86% (n=86) +30% 
P<0.01 
MPR* 84% (n=49) 94% (n=81) +10% 
P=0.086 
PDC:  Proportion of Days Covered 
MPR:  Medication Possession Ratio 
*Comparison matched for participant identification and medication class 
 
 
 
Table 3. Strategies used to Improve Medication Adherence. 
 
One-on-one appointments with a pharmacist at least 1 time/month 
 Comprehensive medication therapy management 
 Lifestyle Journal 
 Pill box 
Incentive to provide medications for hypertension, hyperlipidemia and diabetes at no cost 
 
 
